Third View Private Wealth LLC Acquires Shares of 22,384 Novartis AG $NVS

Key Points

• Third View Private Wealth LLC bought a new stake of 22,384 shares of Novartis (NYSE:NVS) in Q4, valued at about $3.086 million.
• Several other managers also raised positions—most notably Massachusetts Financial Services added 14,352 shares to hold 113,737 shares (~$15.68M)—and institutional investors collectively own 13.12% of the stock.
• Analysts have an average rating of Hold with a consensus price target of $141.20; the company recently paid an annual dividend of $4.773 (article reports a yield of 306.0% and a DPR of 43.02%).

Third View Private Wealth LLC acquired a new stake in shares of Novartis AG (NYSE:NVS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 22,384 shares of the company's stock, valued at approximately $3,086,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Retirement Guys Formula LLC lifted its position in Novartis by 1.1% during the fourth quarter. Retirement Guys Formula LLC now owns 9,655 shares of the company's stock valued at $1,331,000 after buying an additional 108 shares during the period. HF Advisory Group LLC lifted its position in Novartis by 8.9% during the fourth quarter. HF Advisory Group LLC now owns 11,901 shares of the company's stock valued at $1,641,000 after buying an additional 974 shares during the period. Clear Creek Financial Management LLC lifted its position in Novartis by 8.0% during the fourth quarter. Clear Creek Financial Management LLC now owns 2,767 shares of the company's stock valued at $381,000 after buying an additional 206 shares during the period. Carnegie Investment Counsel lifted its position in Novartis by 1.6% during the fourth quarter. Carnegie Investment Counsel now owns 12,434 shares of the company's stock valued at $1,714,000 after buying an additional 200 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in Novartis by 14.4% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 113,737 shares of the company's stock valued at $15,681,000 after buying an additional 14,352 shares during the period. Hedge funds and other institutional investors own 13.12% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. TD Cowen reissued a "hold" rating on shares of Novartis in a research report on Tuesday, February 17th. Wall Street Zen lowered Novartis from a "buy" rating to a "hold" rating in a research report on Saturday, February 7th. DZ Bank downgraded Novartis from a "strong-buy" rating to a "hold" rating in a report on Monday, February 9th. Sanford C. Bernstein upgraded Novartis to a "hold" rating in a report on Thursday, March 19th. Finally, Citigroup restated a "buy" rating on shares of Novartis in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $141.20.

Novartis Price Performance

Shares of NYSE:NVS opened at $154.31 on Tuesday. Novartis AG has a 1-year low of $104.93 and a 1-year high of $170.46. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.12 and a quick ratio of 0.89. The business has a fifty day moving average price of $157.17 and a 200-day moving average price of $142.29. The company has a market capitalization of $325.98 billion, a PE ratio of 21.55, a PEG ratio of 2.64 and a beta of 0.52.

Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings results on Tuesday, February 3rd. The company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.04. Novartis had a return on equity of 40.53% and a net margin of 25.65%.The firm had revenue of $13.86 billion during the quarter, compared to the consensus estimate of $13.85 billion. During the same period last year, the company earned $1.98 earnings per share. The company's revenue was up 1.4% on a year-over-year basis. As a group, equities analysts expect that Novartis AG will post 8.45 EPS for the current fiscal year.

Novartis Dividend Announcement

The business also recently declared an annual dividend, which was paid on Monday, March 16th. Stockholders of record on Wednesday, March 11th were issued a dividend of $4.773 per share. The ex-dividend date was Wednesday, March 11th. This represents a dividend yield of 306.0%. Novartis's dividend payout ratio (DPR) is presently 43.02%.

Novartis Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company's activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.